A pilot study of Octreotide LAR vs. octreotide tid for pain and quality of life in chronic pancreatitis

What Was Tested

Researchers studied Octreotide in the context of chronic pain: fibromyalgia & crps in this controlled clinical trial publication.

Chronic abdominal pain is the most difficult management issue in patients with chronic pancreatitis.

Recently, a long-acting depo-formulated version of octreotide has been developed that can be given as a once monthly intramuscular injection, Octreotide LAR(R) (O-LAR) rather than as a thrice daily subcutaneous injection (octreotide short-acting, O-SA).

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Seven advanced chronic pancreatitis patients with daily, severe abdominal pain who had previously responded to O-SA were recruited from the pancreas clinics of the University of Florida and monitored for one month on O-SA and for four months while on O-LAR.

Each patient served as his/her own control as this was a paired data set.

How the Study Was Run

In design terms this was a open-label and pilot study.

Being open-label, the Octreotide study did not mask who received what.

It is described as a pilot, a small early test of whether a larger Octreotide study would be practical.

A time span of one month appears in the methods.

What Was Measured

The subject headings attached to it are Abdominal Pain, Gastrointestinal Agents, Octreotide, Pancreatitis, Chronic, Pilot Projects and Quality of Life.

What This Means in Plain Language

The paper is an open-label and pilot study of Octreotide in people with chronic pain: fibromyalgia & crps over one month.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (JOP : Journal of the pancreas), a journal based in England.

More context: the Octreotide compound page, Chronic pain: fibromyalgia & CRPS research.